×

Early movers: YHOO, ULTA, CBS, LNKD, MET, AZN, LLY & more

Traders work on the floor of the New York Stock Exchange.
Brendan McDermid | Reuters
Traders work on the floor of the New York Stock Exchange.

Check out which companies are making headlines before the bell:

Under Armour — A two-for-one stock split takes effect Friday for the apparel maker's shares. Holders will get two shares of a new non-voting class "C" for every share of the "old" Under Armour (UA) they now hold.

Yahoo — Sources tell CNBC that Verizon may come forth with a bid for Yahoo as soon as next week, while there have been reports of interest from companies like Alphabet and Time as well as private equity firms Bain and TPG.

Ruby Tuesday — Ruby Tuesday reported adjusted quarterly profit of 3 cents per share, 2 cents below estimates, while the restaurant chain's revenue also missed forecasts. The company cites weather factors as cutting into sales, and also cut its annual outlook.

Gap — Gap reported March comparable store sales fell 6 percent, with the apparel retailer calling the month "challenging." The parent of Gap, Banana Republic, and Old Navy said it was taking steps to improve its results throughout its brand portfolio.

Ulta Salon — The specialty retailer will join the S&P 500 index after the close of trading on Apr. 15. It will replace hospital operator Tenet Healthcare, which will move to the S&P MidCap 400 to replace Jarden. Jarden is in the process of being acquired by Newell Rubbermaid.

CBS — RBC began coverage on CBS with an "outperform" rating, pointing to "top notch content" and new earnings streams. In the same report, RBC rated Time Warner and 21st Century Fox "outperform," while rating Viacom "underperform."

LinkedIn — The stock was downgraded to "neutral" from "buy" at MKM Partners, which said growth in online job postings appears to have peaked. MKM does remain positive on LinkedIn long-term.

Intercept Pharmaceuticals — The drug maker's shares may benefit after an FDA panel voted unanimously to recommend accelerated approval of its liver treatment Ocaliva.

Depomed — Depomed now has activist investor Starboard Value as a 6.8 percent stakeholder, with Starboard saying it would nominate a slate of directors to the drug maker's board. The investment makes Starboard Depomed's third largest shareholder.

MetLife — The government will appeal a judge's ruling that lifted the insurance company's so-called "SIFI" designation removed. Treasury Secretary Jack Lew rejects MetLife's contention that it is not a systemically important financial institution.

AstraZeneca, Eli Lilly — The drug makers said they would move a clinical trial for a new Alzheimer's drug forward after initial testing did not show any harmful side effects.

Valeant Pharmaceuticals — Valeant is not selling its Bausch & Lomb unit, according to investor Bill Ackman. He told CNBC that the vision products brand is a "core asset" and that the company is only seeking to sell non-core assets.

WD-40 — The company reported quarterly profit of 94 cents per share for its second quarter, 8 cents above estimates, though revenue came in below forecasts. The lubricant maker also raised its full year earnings forecast.

Alliance Fiber Optic Products — Corning is offering to buy the fiber optic parts maker for $350 million or $18.50 per share, 20 percent over Alliance's Thursday closing price.